BR112014020659A2 - variantes do lantibiótico mu1140 e outros lantibióti-cos com propriedades farmacológicas e características estructurais melhoradas - Google Patents

variantes do lantibiótico mu1140 e outros lantibióti-cos com propriedades farmacológicas e características estructurais melhoradas

Info

Publication number
BR112014020659A2
BR112014020659A2 BR112014020659A BR112014020659A BR112014020659A2 BR 112014020659 A2 BR112014020659 A2 BR 112014020659A2 BR 112014020659 A BR112014020659 A BR 112014020659A BR 112014020659 A BR112014020659 A BR 112014020659A BR 112014020659 A2 BR112014020659 A2 BR 112014020659A2
Authority
BR
Brazil
Prior art keywords
amino acid
lantibiotic
variants
lantibiotics
structural characteristics
Prior art date
Application number
BR112014020659A
Other languages
English (en)
Portuguese (pt)
Inventor
Leif Smith James
D Hillman Jeffrey
R Wilson Stanford Shawanda
Original Assignee
Oragenics Inc
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oragenics Inc, Texas A & M Univ Sys filed Critical Oragenics Inc
Publication of BR112014020659A2 publication Critical patent/BR112014020659A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G4/123—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01001—Alcohol dehydrogenase (1.1.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Agronomy & Crop Science (AREA)
  • Biomedical Technology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
BR112014020659A 2012-02-27 2013-02-22 variantes do lantibiótico mu1140 e outros lantibióti-cos com propriedades farmacológicas e características estructurais melhoradas BR112014020659A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603693P 2012-02-27 2012-02-27
US201261603661P 2012-02-27 2012-02-27
PCT/US2013/027336 WO2013130349A1 (en) 2012-02-27 2013-02-22 Variants of the lantibiotic mu1140 and other lantibiotics with improved pharmacological properties and structural features

Publications (1)

Publication Number Publication Date
BR112014020659A2 true BR112014020659A2 (pt) 2017-06-27

Family

ID=49083172

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014020659A BR112014020659A2 (pt) 2012-02-27 2013-02-22 variantes do lantibiótico mu1140 e outros lantibióti-cos com propriedades farmacológicas e características estructurais melhoradas
BR112014020656A BR112014020656A2 (pt) 2012-02-27 2013-02-22 terapia de substituição para cárie dentária

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112014020656A BR112014020656A2 (pt) 2012-02-27 2013-02-22 terapia de substituição para cárie dentária

Country Status (10)

Country Link
US (2) US9260488B2 (cg-RX-API-DMAC10.html)
EP (3) EP3219325B1 (cg-RX-API-DMAC10.html)
JP (2) JP6297506B2 (cg-RX-API-DMAC10.html)
CN (2) CN104302307B (cg-RX-API-DMAC10.html)
AU (2) AU2013226402B2 (cg-RX-API-DMAC10.html)
BR (2) BR112014020659A2 (cg-RX-API-DMAC10.html)
CA (2) CA2865395A1 (cg-RX-API-DMAC10.html)
HK (2) HK1205519A1 (cg-RX-API-DMAC10.html)
MX (2) MX358060B (cg-RX-API-DMAC10.html)
WO (2) WO2013130349A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529344A (ja) * 2016-07-15 2019-10-17 イントレキソン コーポレーション ランチビオティックバリアントおよびその使用
US10577399B2 (en) 2016-10-28 2020-03-03 The Texas A&M University System Modified lantibiotics and methods of making and using the modified lantibiotics
WO2020090045A1 (ja) * 2018-10-31 2020-05-07 株式会社村田製作所 抗グラム陰性菌化合物
AU2019371455B2 (en) * 2018-11-01 2022-01-13 Biofouling Technologies, Inc. Durable biofouling protection
CA3128389A1 (en) * 2019-03-08 2020-09-17 Fraunhofer Usa, Inc. Novel antimicrobial lantibiotic peptide and uses thereof
CN118490568B (zh) * 2024-07-16 2024-10-18 南昌怀特科技有限公司 一种用于牙齿美白的抑菌凝胶及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US5516682A (en) 1988-07-05 1996-05-14 University Of Maryland Subtilin variant of enhanced stability and activity
GB9423404D0 (en) 1994-11-19 1995-01-11 Biotech & Biolog Scien Res Production of nisin
US20060198793A1 (en) 1997-06-10 2006-09-07 University Of Florida Research Foundation Antimicrobial polypeptide, nucleic acid, and methods of use
US6964760B2 (en) 1997-06-10 2005-11-15 University Of Florida Research Foundation Antimicrobial polypeptide, nucleic acid, and methods of use
US5932469A (en) * 1997-06-10 1999-08-03 University Of Florida Antimicrobial polypeptide, nucleic acid, and methods of use
US6251478B1 (en) 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
EP1483366B1 (en) * 2002-02-22 2010-04-14 Blis Technologies Limited Antimicrobial composition
US20090215985A1 (en) * 2005-08-12 2009-08-27 Oragenics, Inc. Differentially protected orthogonal lanthionine technology
EP1915389B1 (en) 2005-08-12 2011-06-08 Oragenics, Inc. Differentially protected orthogonal lanthionine technology
WO2007044745A1 (en) 2005-10-11 2007-04-19 Biosynexus Incorporated Lantibiotic and mupirocin compositions for treating bacterial infections
WO2008151434A1 (en) * 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
AU2008319177B2 (en) * 2007-07-20 2012-07-05 Regents Of The University Of Minnesota Lantibiotics from bifidobacterium longum and uses thereof
IE20080365A1 (en) * 2008-05-09 2010-03-16 Univ College Cork Nat Univ Ie Nisin derivatives and the use thereof

Also Published As

Publication number Publication date
WO2013130351A1 (en) 2013-09-06
CA2865405A1 (en) 2013-09-06
AU2013226404A1 (en) 2014-08-21
AU2013226404B2 (en) 2017-11-30
HK1205458A1 (en) 2015-12-18
CA2865395A1 (en) 2013-09-06
MX369443B (es) 2019-11-08
CN104321338A (zh) 2015-01-28
US20150044146A1 (en) 2015-02-12
CA2865405C (en) 2021-11-16
EP2820036A4 (en) 2016-01-20
AU2013226402B2 (en) 2017-05-18
JP6297506B2 (ja) 2018-03-20
JP6309902B2 (ja) 2018-04-11
EP3219325A1 (en) 2017-09-20
EP3219325B1 (en) 2019-11-06
AU2013226402A1 (en) 2014-08-21
EP2833902A4 (en) 2016-04-06
CN104302307A (zh) 2015-01-21
JP2015509715A (ja) 2015-04-02
EP2820036A1 (en) 2015-01-07
JP2015509945A (ja) 2015-04-02
CN104321338B (zh) 2018-10-19
EP2820036B1 (en) 2018-06-06
US9963488B2 (en) 2018-05-08
HK1205519A1 (en) 2015-12-18
US9260488B2 (en) 2016-02-16
WO2013130349A1 (en) 2013-09-06
MX2014010151A (es) 2015-01-14
MX358060B (es) 2018-08-03
WO2013130349A8 (en) 2014-01-09
MX2014010143A (es) 2015-04-08
EP2833902A1 (en) 2015-02-11
BR112014020656A2 (pt) 2017-06-27
US20150125503A1 (en) 2015-05-07
CN104302307B (zh) 2018-10-26

Similar Documents

Publication Publication Date Title
BR112013029269A8 (pt) combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2
BR112016013299A2 (pt) Composto
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112013031268A8 (pt) polipeptídeos
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112015002372A2 (pt) composições e métodos para a redução do teor de álcool no sangue
PE20150201A1 (es) Proteinas del factor 21 de crecimiento del fibroblasto
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112014004726A2 (pt) combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
BR112015030229A2 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112014003640A8 (pt) métodos para perda de peso e composições cetogênicas
BR112013022213A2 (pt) administração parenteral de tapentadol
BR112015018335A2 (pt) Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
BR112015017909A2 (pt) redução do risco de doença autoimune

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2554 DE 17/12/2019.